3-Point Analysis | The Ranitidine impact on pharma companies

The US FDA  found a carcinogenic substance in some samples of acidity medicine Ranitidine.

Ranitidine had a knee-jerk impact on some of the Indian pharma and API companies. The overall ranitidine market for Indian companies is worth nearly Rs 200 crore.

Sakshi Batra does a 3-Point Analysis of why this drug is under the lens and what it could mean for pharma and API companies.